X

Drug Profile

EM 221

Alternative Names: EM-221

Latest Information Update: 03 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mochida Pharmaceutical
Developer EuMentis Therapeutics
Class Neuroprotectants; Small molecules
Mechanism of Action Phosphodiesterase 10A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Gilles de la Tourette's syndrome
Phase I CNS disorders

Most Recent Events

16 Feb 2023 Phase-I clinical trials in CNS disorders in USA (PO)
16 Feb 2023 Phase-II clinical trials in Gilles de la Tourette's syndrome in USA (PO)
30 Sep 2022 Eumentis Pharmaceuticals plans phase II clinical trials in Tourette Syndrome in 3rd quarter of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com